Literature DB >> 33989039

MRI features of breast implant-associated anaplastic large cell lymphoma.

Anna Rotili1, Federica Ferrari1, Luca Nicosia1, Filippo Pesapane1, Valentina Tabanelli2, Stefano Fiori2, Anna Vanazzi3, Lorenza Meneghetti1, Francesca Abbate1, Antuono Latronico1, Enrico Cassano1.   

Abstract

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare and newly recognized subtype of T cell Non-Hodgkin Lymphoma (NHLs) associated with breast implants.The mechanism involved in the development of this kind of lymphoma is still uncertain.BIA-ALCL is generally an indolent disease localized to the breast implant and its capsule and effectively treated with capsulectomy alone without chemotherapy.Clinically, BIA-ALCL may typically present a sudden-onset breast-swelling secondary to periimplant effusion. The minority of BIA-ALCL patients present a more aggressive mass-forming subtype, for which systemic therapy is mandatory.Despite the number of cases has recently increased, BIA-ALCL remains a rare disease described mainly in several case reports and small case series.Breast imaging, including mammography, ultrasound and breast MRI are routinely used in the screening of breast cancer; however, guidelines for the imaging and pathological diagnosis of this disease have only recently been proposed and included in the 2019 National Comprehensive Cancer Network (NCCN) consensus guidelines for BIA-ALCL.The main purpose of this pictorial is to illustrate the MRI signs of BIA-ALCL and correlate them with the corresponding pathology features in order to improve the knowledge of the principals MRI features of this type of lymphoma.

Entities:  

Mesh:

Year:  2021        PMID: 33989039      PMCID: PMC9327767          DOI: 10.1259/bjr.20210093

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.629


  13 in total

1.  Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant.

Authors:  J A Keech; B J Creech
Journal:  Plast Reconstr Surg       Date:  1997-08       Impact factor: 4.730

2.  Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.

Authors:  Naoki Oishi; Garry S Brody; Rhett P Ketterling; David S Viswanatha; Rong He; Surendra Dasari; Ming Mai; Hailey K Benson; Christopher A Sattler; Rebecca L Boddicker; Ellen D McPhail; N Nora Bennani; Christin A Harless; Kuldeep Singh; Mark W Clemens; L Jeffrey Medeiros; Roberto N Miranda; Andrew L Feldman
Journal:  Blood       Date:  2018-06-19       Impact factor: 22.113

3.  2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Authors:  Mark W Clemens; Eric D Jacobsen; Steven M Horwitz
Journal:  Aesthet Surg J       Date:  2019-01-31       Impact factor: 4.283

Review 4.  Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients.

Authors:  Beatriz E Adrada; Roberto N Miranda; Gaiane Margishvili Rauch; Elsa Arribas; Rashmi Kanagal-Shamanna; Mark W Clemens; Michelle Fanale; Nisreen Haideri; Eid Mustafa; John Larrinaga; Neal R Reisman; Jesse Jaso; M James You; Ken H Young; L Jeffrey Medeiros; Wei Yang
Journal:  Breast Cancer Res Treat       Date:  2014-07-30       Impact factor: 4.872

5.  Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012-2018.

Authors:  Colleen M McCarthy; Nilsa Loyo-Berríos; Ali A Qureshi; Erin Mullen; Gayle Gordillo; Andrea L Pusic; Binita S Ashar; Katie Sommers; Mark W Clemens
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

6.  Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Authors:  Mark W Clemens; L Jeffrey Medeiros; Charles E Butler; Kelly K Hunt; Michelle A Fanale; Steven Horwitz; Dennis D Weisenburger; Jun Liu; Elizabeth A Morgan; Rashmi Kanagal-Shamanna; Vinita Parkash; Jing Ning; Aliyah R Sohani; Judith A Ferry; Neha Mehta-Shah; Ahmed Dogan; Hui Liu; Nora Thormann; Arianna Di Napoli; Arianna DiNapoli; Stephen Lade; Jorge Piccolini; Ruben Reyes; Travis Williams; Colleen M McCarthy; Summer E Hanson; Loretta J Nastoupil; Rakesh Gaur; Yasuhiro Oki; Ken H Young; Roberto N Miranda
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

7.  ACR Appropriateness Criteria® Breast Implant Evaluation.

Authors:  Ana P Lourenco; Linda Moy; Paul Baron; Aarati D Didwania; Roberta M diFlorio; Samantha L Heller; Anna I Holbrook; Alana A Lewin; Tejas S Mehta; Bethany L Niell; Priscilla J Slanetz; Ashley R Stuckey; Daymen S Tuscano; Nina S Vincoff; Susan P Weinstein; Mary S Newell
Journal:  J Am Coll Radiol       Date:  2018-05       Impact factor: 5.532

8.  Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

Authors:  C Laurent; A Delas; P Gaulard; C Haioun; A Moreau; L Xerri; A Traverse-Glehen; T Rousset; I Quintin-Roue; T Petrella; J F Emile; N Amara; P Rochaix; M P Chenard-Neu; A M Tasei; E Menet; H Chomarat; V Costes; L Andrac-Meyer; J F Michiels; C Chassagne-Clement; L de Leval; P Brousset; G Delsol; L Lamant
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

Review 9.  Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review.

Authors:  Ashley N Leberfinger; Brittany J Behar; Nicole C Williams; Kevin L Rakszawski; John D Potochny; Donald R Mackay; Dino J Ravnic
Journal:  JAMA Surg       Date:  2017-12-01       Impact factor: 14.766

10.  Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.

Authors:  Piers Blombery; Ella Thompson; Georgina L Ryland; Rachel Joyce; David J Byrne; Christine Khoo; Stephen Lade; Mark Hertzberg; Greg Hapgood; Paula Marlton; Anand Deva; Geoffrey Lindeman; Stephen Fox; David Westerman; Miles Prince
Journal:  Oncotarget       Date:  2018-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.